These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 34726191)
1. Bladder preservation in urothelial carcinoma: current trends and future directions. Goodstein T; Wang SJ; Lee CT Curr Opin Support Palliat Care; 2021 Dec; 15(4):253-259. PubMed ID: 34726191 [TBL] [Abstract][Full Text] [Related]
2. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease? Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973 [TBL] [Abstract][Full Text] [Related]
3. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Koga F; Kihara K Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269 [TBL] [Abstract][Full Text] [Related]
4. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684 [TBL] [Abstract][Full Text] [Related]
5. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001 [TBL] [Abstract][Full Text] [Related]
6. Can bladder preservation therapy come to the center stage? Inamoto T; Ibuki N; Komura K; Juri H; Yamamoto K; Yamamoto K; Fujita K; Nonomura N; Narumi Y; Azuma H Int J Urol; 2018 Feb; 25(2):134-140. PubMed ID: 29171098 [TBL] [Abstract][Full Text] [Related]
7. Selective organ preservation in muscle-invasive bladder cancer: review of the literature. Khosravi-Shahi P; Cabezón-Gutiérrez L Surg Oncol; 2012 Mar; 21(1):e17-22. PubMed ID: 22088598 [TBL] [Abstract][Full Text] [Related]
8. [Muscle invasive bladder cancer and bladder preservation protocols. Where are we?]. Domínguez Escrig JL Arch Esp Urol; 2020 Dec; 73(10):986-995. PubMed ID: 33269717 [TBL] [Abstract][Full Text] [Related]
9. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162 [TBL] [Abstract][Full Text] [Related]
10. [The first experience in Hungary with split-course multimodal treatment in high risk bladder cancer]. Fazekas F; Bíró K; Ágoston P; Nagyiványi K; Gonda G; Buzogány I; Beöthe T Orv Hetil; 2021 Dec; 162(50):2017-2022. PubMed ID: 34896984 [TBL] [Abstract][Full Text] [Related]
11. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion]. Słojewski M Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306 [TBL] [Abstract][Full Text] [Related]
12. Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy. Hwang EC; Sathianathen NJ; Imamura M; Kuntz GM; Risk MC; Dahm P Cochrane Database Syst Rev; 2019 May; 5(5):CD013336. PubMed ID: 31111956 [TBL] [Abstract][Full Text] [Related]
13. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. Hamad J; McCloskey H; Milowsky MI; Royce T; Smith A Int Braz J Urol; 2020; 46(2):169-184. PubMed ID: 31961624 [TBL] [Abstract][Full Text] [Related]